$PRTA

Isaacs Michael John sold $71K of PRTA

Isaacs Michael John (General Counsel & Company Sec.) sold 8,386 shares of PROTHENA CORP PUBLIC LTD CO (PRTA) at $8.47 on 2026-07-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Isaacs Michael John
Published Jul 31, 2026, 12:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PRTA
Neutral
high confidence
Mentioned
$PRTA
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRTANeutralLow
01

Why it matters

The only new information is the transaction size, price, and post-sale holdings; there is no accompanying guidance, deal, regulatory action, or operational update.

02

Market read

Insider selling headlines can move sentiment, but 10b5-1 context usually reduces signal strength versus unscheduled sales.

03

What to watch

The filing does not disclose any change in business outlook, valuation, or risk factors; traders should avoid extrapolating fundamentals from a single planned sale.

Relevance 2/10Novelty 3/10Timing: filed 2026-07-30 after the 2026-07-29 sale

Background

The article is a SEC Form 4 insider transaction disclosure for Prothena (PRTA), reporting an open-market sale by an officer under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$PRTANeutralHigh confidence
Context

Prothena (PRTA) disclosed an insider open-market sale by General Counsel Michael John Isaacs of 8,386 shares at $8.4731 on 2026-07-29.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is an insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and the article provides no new company-specific catalyst beyond the sale details.

Market effects

No sector read-through is provided; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • PROTHENA CORP PUBLIC LTD CO

    Company subject of the Form 4 insider transaction disclosure.

  • Michael John Isaacs

    General Counsel & Company Secretary reporting the sale.

  • Rule 10b5-1 plan

    Pre-arranged plan indicating the sale was scheduled in advance.

Related articles

$PRTAMed

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

Prothena (PRTA) reported Q2 2026 adjusted loss per share of 32 cents, narrower than the Zacks estimate of a 39-cent loss. Revenues were $1.01 million versus $4.4 million a year earlier, mainly collaboration revenue from Bristol Myers Squibb (BMY) for PRX019. Prothena had $330.3 million cash, no debt, and reaffirmed 2026 net cash use guidance of $18-$23 million.

$PRTAMed

PROTHENA CORP PUBLIC LTD CO (PRTA): Results of Operations and Financial Condition

PROTHENA CORP PUBLIC LTD CO (PRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026earningsre.htm EX-99.1 Document Exhibit 99.1 PRESS RELEASE Prothena Reports Second Quarter 2026 Financial Results an d Business Highlights • Net cash used in operating and investing activities was $25.7 million in the second quarter, and net cash provide